-
Measuring Drug Response Beyond Cell Viability
2026-09-22
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell killing are related but non-equivalent dimensions of anticancer drug response. The framework supports more interpretable in vitro studies by aligning assay choice, timing, and analysis with the biological question rather than treating every viability decrease as evidence of cell death.
-
Bacitracin B1670: Protocol and QC Guide
2026-09-22
Bacitracin B1670 provides a defined research reagent for controlled antibacterial assays focused on bacterial cell wall and peptidoglycan synthesis. This guide covers preparation, solvent selection, storage, controls, and quality checks; it is intended for scientific research only and not for diagnostic, clinical, or medical use.
-
Pam3CSK4: TLR1/2 Assays and Optimization
2026-09-21
Pam3CSK4 provides a defined TLR1/2 agonist stimulus for dissecting cytokine release, macrophage nitric oxide production, platelet signaling, and allergy biology. This workflow also shows how to pair receptor-controlled immune activation with emerging somato-autonomic inflammation models without overstating what the current evidence proves.
-
CLEC5A and ISG20 in Atherosclerosis
2026-09-21
Zhang et al. integrate GEO expression data, eQTL evidence, Mendelian randomization, and experimental validation to investigate causal regulators of atherosclerosis. The study identifies CLEC5A and ISG20 as genetically supported risk-associated genes and provides evidence that ISG20 is elevated in macrophage- and endothelial-rich atherosclerotic lesions.
-
Rotigotine Hydrochloride: From Receptor to Readout
2026-09-20
Rotigotine hydrochloride connects multi-receptor dopaminergic pharmacology with demanding chemical and functional assay decisions. This guide translates impurity, chirality, stability, model-selection, and endpoint considerations into a practical framework for Parkinson’s disease research.
-
Alternariol (AOH) Workflows for Fibrosis Research
2026-09-19
Build controlled Alternariol experiments that connect foodborne mycotoxin exposure with hepatic stellate-cell remodeling, apoptosis, and CYP1A metabolism. This workflow separates reference-study findings from practical assay recommendations so researchers can compare mechanisms without overinterpreting model-specific results.
-
Gramine: Ferroptosis Workflows in TNBC
2026-09-19
Gramine offers a mechanism-focused route to study ferroptosis in triple-negative breast cancer models, linking CUL3 activity with MTDH stability. This guide converts the reported biology into practical formulation, target-engagement, rescue, and troubleshooting workflows for cancer biology research.
-
LY2109761: TGF-β Receptor I/II Inhibitor
2026-09-18
LY2109761 is a TGF-β receptor type I and II dual inhibitor that blocks receptor kinase activity and downstream Smad2/3 signaling. Its preclinical research profile includes pancreatic cancer, glioblastoma radiosensitization, prostate tumor models, and fibrosis studies, but it is not a clinical or diagnostic product.
-
APEX-RNA-MS Maps RNA Modifications in Cell Structures
2026-09-17
Seo, Dhingani, and Kleiner introduce APEX-RNA-MS, a workflow that combines APEX2 proximity labeling with nucleoside LC-MS to quantify modified RNAs near defined cellular structures. The study links m6A and m5C enrichment to DNA damage foci and shows that modified tRNA populations accumulate with G3BP1 in arsenite-induced stress granules.
-
Adefovir (GS-0393): HBV Mechanism and Research Use
2026-09-17
Adefovir, also known as GS-0393, is an acyclic nucleoside phosphonate used to study HBV DNA polymerase inhibition and renal OAT1 transport. Its research value depends on separating antiviral assay exposure from clinical pharmacokinetics and monitoring renal phosphate-wasting risk.
-
Carvedilol Phosphate in Hepatic IRI Research
2026-09-17
Carvedilol Phosphate is a non-selective beta blocker research reagent with additional alpha-1 adrenergic activity and defined formulation parameters. It is useful for cardiovascular pharmacology research and hypothesis-driven ischemia-reperfusion injury model design, but the cited hepatic study does not establish carvedilol as a treatment for liver IRI.
-
Cdc42–GSK-3β Signaling in Kidney Fibrosis
2026-09-16
The 2024 Advanced Science study identifies daphnepedunin A, a natural daphne diterpenoid, as an anti-fibrotic lead that targets Cdc42 and suppresses downstream GSK-3β/β-catenin signaling. Its combination of bioassay-guided chemistry, thermal proteome profiling, renal fibroblast assays, and unilateral ureteral obstruction models provides a mechanistic framework for evaluating Cdc42 as a kidney-fibrosis target.
-
SN-38 Disrupts FUBP1–FUSE DNA Binding
2026-09-15
The reference study identifies a mechanism beyond canonical topoisomerase I poisoning: camptothecin and its active metabolite SN-38 interfere with binding of the oncogenic transcriptional regulator FUBP1 to the single-stranded DNA element FUSE. Biochemical and cellular experiments suggest that this disruption can deregulate FUBP1-controlled genes in hepatocellular carcinoma, providing a framework for studying how SN-38 activity may depend on tumor transcriptional programs.
-
C34 TLR4 Inhibitor: Practical Assay Guide
2026-09-15
C34 is a selective TLR4 inhibitor for separating TLR4-driven inflammation from broader cytokine suppression in macrophage, enterocyte, tissue, and microglial assays. This workflow-focused guide covers dosing, controls, cross-model interpretation, and troubleshooting for inflammatory signaling research.
-
L-Alanyl-L-Glutamine: Assay Workflow Guide
2026-09-14
This scenario-based guide explains how L-Alanyl-L-Glutamine, SKU B8228, can help researchers standardize aqueous nutrient conditions in cell viability, proliferation, and cytotoxicity workflows. It covers solvent compatibility, stock preparation, controls, interpretation, and practical vendor-selection criteria without assuming that a nutritional supplement will directly improve every assay.